SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Stack of documents. Pile of waste documents earmarked for Recycling.
Patents
Patent Thickets in Federal Government’s Crosshairs as Election 2024 Looms
Congress, the Federal Trade Commission and the U.S. Patent and Trademark Office are all targeting Big Pharma’s practice of filing multiple, overlapping patents that stifle generic and biosimilar competition.
August 28, 2024
 · 
7 min read
 · 
Greg Slabodkin
Feb 2, 2020 South San Francisco / CA / USA - Genentech headquarters in Silicon Valley; Genentech, Inc., is an American biotechnology corporation which became a subsidiary of Roche in 2009
Layoffs
Genentech to Lay Off 93 in San Francisco
Genentech’s latest layoffs are the second round of workforce reductions this year, following the company’s announcement in April that it was letting go around 3% of employees.
August 28, 2024
 · 
1 min read
 · 
Angela Gabriel
Sign in front of Pfizer in Quebec, Canada
Collaboration
Pfizer Partners With Flagship’s Quotient to Leverage Genetics Against Heart, Renal Diseases
Quotient Therapeutics’ platform targets somatic mutations, which the startup contends can help identify a broader scope of genes potentially associated with disease phenotypes. Wednesday’s agreement is part of an existing partnership between Pfizer and Flagship Pioneering.
August 28, 2024
 · 
2 min read
 · 
Tristan Manalac
3D illustration of antibodies
Series A
Navigator Closes $100M Series A, Targets Autoimmune Market With Potential Best-in-Class Bispecific Antibody
Navigator Medicine is looking to push its lead asset NAV-240 targeting immune-mediated diseases through to clinical studies “in the coming months,” which the startup in-licensed from a South Korean biotech for $20 million upfront.
August 28, 2024
 · 
2 min read
 · 
Tristan Manalac
Illustration of fractional worker sitting in home office while working
Job Trends
Difficult Market Turns More Biopharma Leaders to Fractional Roles, Say Experts
For reasons including downsizing, avoiding retirement and a tight labor market, senior-level biopharma professionals are increasingly turning to fractional roles, according to two recruitment experts.
August 28, 2024
 · 
4 min read
 · 
Angela Gabriel
Nurse inserts an IV line into a patient with a mask
COVID-19
FDA Limits Use of Invivyd’s COVID-19 Prophylactic as New Variants Dominate
The regulator’s restrictions come as the U.S. is experiencing a surge in cases. Invivyd also announced updated Phase III data for Pemgarda, touting an 84% relative reduction in symptomatic COVID-19.
August 28, 2024
 · 
2 min read
 · 
Tristan Manalac
Signage at Pfizer's world headquarters in New York City
Business
Pfizer Launches Direct-to-Consumer Portal for Migraine, Flu, COVID-19 Products
The company joins Eli Lilly in offering its own digital platform to more directly connect to patients, allowing them easier access to healthcare providers and prescription drugs.
August 28, 2024
 · 
2 min read
 · 
Tristan Manalac
Podcast
A Tough Ending, New Beginnings and China-U.S. Biopharma Relations
Well-financed startup Tome is winding down operations just as two new companies, Borealis Biosciences and GondolaBio, are launching. Meanwhile, in the midst of already tense relations with China, House lawmakers raise the alarm about U.S. companies working with the country’s military on trials.
August 28, 2024
 · 
1 min read
 · 
Heather McKenzie
Pictured: A syringe broken in half with long hallway in background/Nicole Bean for BioSpace
Vaccines
Moderna Lays Foundations for Growth, but Can It Turn Strategy Into Execution?
The vaccine maker is competing with well-established rivals in markets that have a mix of demand issues as well as commercial and structural headwinds, as the biotech looks to establish new growth drivers.
August 28, 2024
 · 
6 min read
 · 
Nick Paul Taylor
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS